Amgen (AMGN) & Allergen (AGN) Report Phase 3 Data On Biosimilar Trastuzumab Candidate ABP 980
Tweet Send to a Friend
Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced data from a Phase 3 study evaluating the efficacy and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
